{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:13:17Z","timestamp":1788624797737,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the achievement of complete remission (CR) and the management for relapsed cases in the treatment of idiopathic inflammatory myopathies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 132 patients was retrospectively analysed. CR was defined as no evidence of disease activity in all involved organs for a continuous period of six months. Relapse was defined as a dose increase of glucocorticoids of &amp;gt;50% and an increase in prednisolone equivalent to &amp;gt;0.4\u00a0mg\/kg\/day. Clinical data were collected by electrical chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-eight (66.7%) patients achieved CR with initial treatment. Forty-three patients experienced at least one relapse. The anti-aminoacyl tRNA synthetase antibody was positively and achieving CR was negatively associated with relapse (hazard ratio: 3.02 and odds ratio: 0.17, respectively). Re-induction therapies were classified into three groups: high-dose glucocorticoid plus one immunosuppressant (IS)\/biologics (H\u2009+\u20091IS, n\u2009=\u200912), moderate-dose glucocorticoid plus two IS\/biologics (M\u2009+\u20092IS, n\u2009=\u200912), and moderate-dose glucocorticoid plus one IS\/biologics (M\u2009+\u20091IS, n\u2009=\u200919). The frequency of second relapse was least in the M\u2009+\u20092IS regimen. The concomitant use of two IS\/biologics did not increase the incidence of severe adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CR was achieved in two-thirds of idiopathic inflammatory myopathies patients. Achieving CR was protective for relapse. Combination therapy with two IS\/biologics might be preferable in relapsed cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag067","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:17:08Z","timestamp":1786965428000},"source":"Crossref","is-referenced-by-count":0,"title":["Complete remission and relapse in the treatment of idiopathic inflammatory myopathies: A retrospective cohort study"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-0443","authenticated-orcid":false,"given":"Naoki","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Hanazawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuka","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"2026090512064935600_ref1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Prim"},{"key":"2026090512064935600_ref2","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/17512433.2015.1061429","article-title":"Remission in rheumatoid arthritis: is it all the same?","volume":"8","author":"Gul","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026090512064935600_ref3","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2026090512064935600_ref4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ARD-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026090512064935600_ref5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/LUPUS-2021-000538","article-title":"DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026090512064935600_ref6","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/S40744-023-00601-W","article-title":"Targeting DORIS remission and LLDAS in SLE: a review","volume":"10","author":"Parra S\u00e1nchez","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026090512064935600_ref7","doi-asserted-by":"publisher","first-page":"102257","DOI":"10.1016\/j.coph.2022.102257","article-title":"Current and new targets for treating myositis","volume":"65","author":"Moghadam-Kia","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"2026090512064935600_ref8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2026090512064935600_ref9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/08916930600622884","article-title":"Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies","volume":"39","author":"Yoshifuji","year":"2006","journal-title":"Autoimmunity."},{"key":"2026090512064935600_ref10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","article-title":"Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody","volume":"37","author":"Isoda","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026090512064935600_ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026090512064935600_ref12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume-title":"Rheumatology","author":"Oldroyd","year":"2022"},{"key":"2026090512064935600_ref13","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/ANNRHEUMDIS-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026090512064935600_ref14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2026090512064935600_ref15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026090512064935600_ref16","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/CHEST.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest."},{"key":"2026090512064935600_ref17","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026090512064935600_ref21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2026090512064935600_ref22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag067\/70725357\/roag067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag067\/70725357\/roag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T16:06:55Z","timestamp":1788624415000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/advance-article\/doi\/10.1093\/mr\/roag067\/8767231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.1093\/mr\/roag067","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"roag067"}}